APEIRON Capital’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
APEIRON Capital's NKTR Position: Q3 2026 in Review
APEIRON Capital reduced its Nektar Therapeutics (NKTR) stake by 52% in Q3 2026, selling an estimated $3.86M and leaving 51,400 shares worth $3.59M. The position accounts for 4.87% of the portfolio, ranked #6.
APEIRON Capital first reported a position in NKTR in Q2 2026 and has held it in 2 quarters since. The position peaked at $7.43M in Q2 2026. 168 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- APEIRON Capital held 51,400 shares of Nektar Therapeutics worth $3.59M as of Q3 2026.
- APEIRON Capital sold 55,031 Nektar Therapeutics shares in Q3 2026, an estimated $3.86M.
- Nektar Therapeutics made up 4.87% of APEIRON Capital's portfolio in Q3 2026, its #6 holding.
- APEIRON Capital first reported a position in Nektar Therapeutics in Q2 2026 and has held it in 2 quarters since.
- APEIRON Capital's Nektar Therapeutics position peaked at $7.43M in Q2 2026.
- 168 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on APEIRON Capital's 13F filing for Q3 2026, filed 4 Nov 2026.